Related Experiment Video
Updated: Jun 10, 2025
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
19.6K
Metformin: Beyond Type 2 Diabetes Mellitus.
1Department of Physiology, Medical College for Women and Hospital, Dhaka, BGD.
Cureus
|October 18, 2024
Summary
Metformin, a common diabetes drug, shows promise for treating non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, and liver cancer. Further research and guidelines are recommended for its use in liver conditions.
Area of Science:
- Pharmacology and Gastroenterology
Background:
- Metformin is a primary treatment for type 2 diabetes mellitus, polycystic ovarian syndrome, and weight management.
- It demonstrates efficacy in managing non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, and various cancers.
Purpose of the Study:
- This review examines metformin's effects on non-alcoholic fatty liver disease, liver cirrhosis, and hepatocellular carcinoma.
- It explores metformin's mechanisms of action and potential therapeutic applications in liver conditions.
Main Methods:
- A narrative review was conducted using literature searches on PubMed, Scopus, and Google.
- Keywords included 'Metformin,' 'NAFLD,' 'liver cirrhosis,' 'hepatocellular carcinoma,' and related terms.
Main Results:
- Metformin enhances liver health by reducing oxidative stress, inflammation (NF-κB), and liver enzymes.
- It improves insulin sensitivity and promotes hepatic lipophagy.
- Potential adverse effects include lactic acidosis and gastrointestinal issues with long-term use or overdose.
Conclusions:
- Metformin offers multifaceted benefits for liver health, targeting inflammation and metabolic dysfunction.
- Further research and specific guidelines are needed to integrate metformin into the management of liver diseases like NAFLD, cirrhosis, and HCC.
- Pharmacovigilance is essential due to potential long-term adverse effects.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
178
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
178
01:22Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
163
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
163
01:06Oral Hypoglycemic Agents: Glinides
142
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
142
01:17Oral Hypoglycemic Agents: Sulfonylureas
194
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
194
01:15Diabetes: Management and Pharmacotherapy
238
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
238